Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Met (Met Proto-Oncogene, Hepatocyte Growth Factor (Hgf) Receptor, Hgfr, Scatter Factor (Sf) Receptor, Hgf/Sf Receptor, Receptor Tyrosine-Protein Kinase C-Met, Papillary Renal Cell Carcinoma 2, Rccp2)] And Anti-[Homo Sapiens Egfr (Epidermal Growth Factor Receptor, Receptor Tyrosine-Protein Kinase Erbb-1, Erbb1, Her1, Her-1, Erbb)], Homo Sapiens Monoclonal Antibody, Bispecific
Head And Neck Squamous Cell Carcinoma
Explore 249 assets in Head And Neck Squamous Cell Carcinoma →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Merus B.V.
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04868877CT.gov Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Met (Met Proto-Oncogene, Hepatocyte Growth Factor (Hgf) Receptor, Hgfr, Scatter Factor (Sf) Receptor, Hgf/Sf Receptor, Receptor Tyrosine-Protein Kinase C-Met, Papillary Renal Cell Carcinoma 2, Rccp2)] And Anti-[Homo Sapiens Egfr (Epidermal Growth Factor Receptor, Receptor Tyrosine-Protein Kinase Erbb-1, Erbb1, Her1, Her-1, Erbb)], Homo Sapiens Monoclonal Antibody, Bispecific (this asset) | Merus B.V. | P1/2 | CC · 41 |
| Cis-Diamminedichloroplatinum Ii | Akeso | P3 | BB |
| Carboplatin | Akeso | P4 | BB |
| Irinotecan | Neonc Technologies, Inc. | P2 | BB |
| Capecitabine | Merck Sharp & Dohme LLC | P2 | BB |
| Tisotumab Vedotin | Seagen, a wholly owned subsidiary of Pfizer | P2 | BB |
| Pembrolizumab | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
| Fluorouracilum | Akeso | P2 | BB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
+42 more in the Head And Neck Squamous Cell Carcinoma cohort
Other indications for Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Met (Met Proto-Oncogene, Hepatocyte Growth Factor (Hgf) Receptor, Hgfr, Scatter Factor (Sf) Receptor, Hgf/Sf Receptor, Receptor Tyrosine-Protein Kinase C-Met, Papillary Renal Cell Carcinoma 2, Rccp2)] And Anti-[Homo Sapiens Egfr (Epidermal Growth Factor Receptor, Receptor Tyrosine-Protein Kinase Erbb-1, Erbb1, Her1, Her-1, Erbb)], Homo Sapiens Monoclonal Antibody, Bispecific
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 54 |
| Esophageal Squamous Cell Carcinoma | — | P1/2 | CC · 43 |
| Head And Neck Cancer | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Met (Met Proto-Oncogene, Hepatocyte Growth Factor (Hgf) Receptor, Hgfr, Scatter Factor (Sf) Receptor, Hgf/Sf Receptor, Receptor Tyrosine-Protein Kinase C-Met, Papillary Renal Cell Carcinoma 2, Rccp2)] And Anti-[Homo Sapiens Egfr (Epidermal Growth Factor Receptor, Receptor Tyrosine-Protein Kinase Erbb-1, Erbb1, Her1, Her-1, Erbb)], Homo Sapiens Monoclonal Antibody, Bispecific in Head And Neck Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-kappa-anti-homo-sapiens-met-met-proto-oncogene-hepatocyte-growth-factor-hgf-receptor-hgfr-scatter-factor-sf-receptor-hgfsf-receptor-receptor-tyrosine-protein-kinase-c-met-papillary-renal-cell-carcinoma-2-rccp2-and-anti-homo-sapiens-egfr-epidermal-growth-factor-receptor-receptor-tyrosine-protein-kinase-erbb-1-erbb1-her1-her-1-erbb-homo-sapiens-monoclonal-antibody-bispecific-head-and-neck-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →